Roflumilast foam for hidradenitis suppurativa in teens and adults
Treatments studied
Part of Infections, Skin clinical trials.
This study tests a foam medication (roflumilast 0.3%) applied to the skin to see if it safely reduces hidradenitis suppurativa (HS) bumps and pain in teens and adults. It might help people with mild-to-moderate HS, especially those who haven't tried this foam before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 12 years old or older.
- Have hidradenitis suppurativa (HS) for at least 3 months, confirmed by a doctor.
- Have 4 to 10 painful bumps or boils from HS, with no 'draining tunnels' (tunnels that leak).
- Agree not to use other HS treatments (like antibiotics, steroid shots, or special washes) during the study.
- If you've had surgery for HS, it must be at least 3 months since the procedure.
- If you can become pregnant, you must use effective birth control and have a negative pregnancy test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether roflumilast foam (a prescription foam) is safe and can reduce inflamed bumps in people with mild-to-moderate hidradenitis suppurativa (HS) who do not have draining tunnels. Participants will stop other HS treatments during the trial.
This trial tests a new cream (EVO101) for people with mild to moderate hidradenitis suppurativa (HS), a skin condition causing painful lumps. It aims to see if the cream can reduce the number of lesions. Participants cannot use certain other HS treatments during the study.
This study tests a new medicine given by injection (anti-IL-17A/F antibody) combined with a laser treatment (non-ablative dot laser) for people with mild to moderate hidradenitis suppurativa (also called HS). The goal is to see if the combination is safe and works better than current options, and might help reduce pain and flare-ups.
This trial tests a new medicine called SCT650C for people with moderate to severe hidradenitis suppurativa (HS). The goal is to see if it can reduce painful bumps and abscesses better than current treatments.
This trial is testing an experimental tablet called LT-002-158 in adults with moderate to severe hidradenitis suppurativa (HS) that hasn't improved enough with standard treatments. The goal is to see if it's safe and helps reduce painful lumps and abscesses.
This study looks at certain immune cells (called MAIT cells) in the skin of people with hidradenitis suppurativa, a painful skin condition. It will compare samples from people before they start a new biologic treatment, and may help doctors understand how these treatments work.
Hear when a new Hidradenitis Suppurativa (HS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.